Ankylosing Spondylitis Market By Drug Class (Non-Steroidal Anti-Inflammatory Drugs {Ibuprofen, Naproxen, Others}, Tumor Necrosis Factor (TNF) Inhibitors {Etanercept, Infliximab, Adalimumab, Golimumab}, Interleukin-17 (IL-17) Inhibitors {Secukinumab, Ixekizumab}, Disease-Modifying Antirheumatic Drugs {Methotrexate, Sulfasalazine}, Corticosteroids, Others), By Route of Administration (Oral, Injectable, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Specialty Clinics, Homecare), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Ankylosing Spondylitis market accounted for USD 6.28 Billion in 2024 and is expected to reach USD 12.55 Billion by 2035, growing at a CAGR of around 6.5% between 2025 and 2035. Ankylosing Spondylitis Market deals with the therapy and treatment of Ankylosing Spondylitis, a rheumatic disease involving the inflammation of the spine and sacroiliac joints that results in pain, stiffness, and limited range of motion. This condition can result in bony ankylosis of the spine, which greatly declines the level of flexibility.

Typically, the market comprises NSAIDs, biologics, and DMARDs to help ease rheumatic disease symptoms and halt or slow down disease progression. The increased rate of diseases and appearance of the new treatment approaches, including TNF inhibitors and IL-17 blockers, are driving the market. Thus, the key players of the industry remain focused on investing in new therapeutic options to fill the gaps in existing treatment methods.

Report Scope:

Market Dynamics

The rising prevalence of ankylosing spondylitis globally boosts the demand for effective therapies.

Ankylosing Spondylitis Market is rapidly developing, primarily because of an increase in the incidence of this disease worldwide. Ankylosing spondylitis is a type of inflammatory arthritis, affecting the spine and other organs/bones wherein they observed an increase in the number of diagnoses which contributed to increased awareness and better diagnostic tools. This has in turn increased the patient’s need for proper treatment options which include biologics and biosimilar drugs. 

The enhanced acknowledgment of disease impact on the quality of life of patients has spurred developments of treatment within the Ankylosing Spondylitis market. Drug manufacturers are working round the clock to come up with new drugs for arthritis since IL-17 and TNF inhibitors provide methodical and long-term pain relief. All these factors coupled with the health care sector implementation of preventive measures to check the diseases are some of the major factors boosting the growth of the market across the globe. 

Advancements in biologics and biosimilars significantly enhance treatment options and patient outcomes.

The Ankylosing Spondylitis Market remains promising, with recent breakthroughs in biologics and biosimilars that enhanced AS’s treatment. The new biologic drugs include TNF inhibitors and IL-17 inhibitors, which are given systematically and eliminate the inflammatory process and halt the progression of this disease. These innovations afford targeted relief as other treatments, for example, NSAIDs, do not help some patients. 

Biosimilars are also making these advanced therapies affordable hence significantly increasing the growth of the Ankylosing Spondylitis market. As patents on major biologics products/ drugs came to an end companies have launched products that are called biosimilars which are as effective but cheaper. In addition to this, the existence of this development promotes both the treatments available and the contest in the sector to improve and invest. In combination with biosimilars, biologics are changing the course of the management of Ankylosing Spondylitis at the international level. 

High treatment costs limit accessibility, particularly in low-income and developing regions

The high treatment cost remains a major issue affecting the Ankylosing Spondylitis Market since it reduces its affordability to a considerable measure in low-income and developing countries. Novel products such as biologics or IL-17 inhibitors, while providing efficacy, are usually costly and thus inaccessible to several inhabitants of these regions. This leads to an imbalance of treatment access and many people receiving poor quality treatment or using conventional treatment methods. 

Weak healthcare reimbursement policies further worsen the situation, because the majority of patients cannot afford long-term treatment in the Ankylosing Spondylitis Market. Research, development, and manufacture of biologics are expensive processes that are part of the biologic prices; penetration of cheap biosimilars has been slow. Solving all these issues will entail unity of efforts between governments, pharmaceutical companies, and healthcare organizations to work together in establishing better forms of affordability and accessibility, especially to less privileged regions. 

Expansion into emerging markets creates new pathways for growth and market diversification

The treatment of Ankylosing Spondylitis presents a growing opportunity to enter new markets and expand activity. Asia-Pacific, Latin America, and the Middle East are emerging markets owing to a developing advanced health care facility, and a rising incidence of Ankylosing Spondylitis disease. They are spending efforts in making healthcare more existent for citizens as well as partnering with the pharmaceutical industries to introduce innovative products like biosimilars. Also, favorable regulation changes in these areas have pushed for speedy approval of new therapies. 

As per the disease incidence for Ankylosing Spondylitis, these markets encompass unmet medical demand to create a global market interest for players. These are; the ability to offer the products at reasonable prices through an affordable pricing structure, a central production facility to prevent high production costs, and engaging regional distributors as part of the marketing strategy. Venturing into new markets quite apart from the fact that it augments the revenue portfolio is also useful in managing the disease burden in the world. Increased education and training for health care professionals along with increased use of technology and research to develop new treatments provide the key driver for the implementation of new treatments. 

The development of personalized medicine solutions enhances effectiveness and attracts more investment.

The Ankylosing Spondylitis Market is set to expand at a robust pace as the concept of personalized medicine solutions leads to improved outcomes and thus increasing proportional investments. Molecular medicine leads to the development of properly targeted individual-specific therapies that can act according to the genes, environment, or lifestyles of individual patients while possessing the least number of side effects. It has greatly transformed the treatment of Ankylosing Spondylitis from a standard approach to a molecule-formatted one. 

Personalized medicine is proving to be progressive it has gained the limelight from many pharmaceutical industries and investors. Targeted therapies have gained significant investment in research and development due to trends such as better patient outcomes and lower development costs. Moreover, the incorporation of advanced technologies in therapy facilitation will continue pushing the growth of the Ankylosing Spondylitis market for Ankylosing Spondylitis through essential biomarkers and genetic profiling technologies.

Industry Experts Opinion

“People living with non-radiographic axial spondyloarthritis and Ankylosing Spondylitis experience pain, stiffness, and fatigue that can limit their daily activities, ability to work, and quality of life, A new treatment option offers the opportunity for more patients to reach their treatment goals”

• Seth Ginsberg, co-founder and president of Global Health Living Foundation and Creaky Joints, U.S.

“Non-radiographic axial spondyloarthritis (nr-axSpA) and Ankylosing Spondylitis (AS) are both forms of axial spondyloarthritis (axSpA), they represent different points along the same disease spectrum and share many clinical features, including similar inflammatory processes that primarily affect the spine and sacroiliac joints.”

• Diana Girnita, M.D., Ph.D., a board-certified rheumatologist

Segment Analysis

Based on Drug Class, the Ankylosing Spondylitis Market is classified as NSAIDs, TNF inhibitors, IL-17 inhibitors, DMARDs, corticosteroids, and others. Of these, drugs in the TNF inhibitors category such as etanercept, infliximab, and adalimumab predominate because they effectively reduce inflammation and arrest the disease. Secukinumab and ixekizumab, as more recent drugs with purposeful mechanisms of action and fewer side effects, are also quickly becoming more popular.

Prescription non-steroidal anti-inflammatory drugs (NSAIDs) are the traditional definitive treatment for pain and stiffness which include; İbuprofen and Naproxen. This segment is expanding because more patients and physicians recognize the differences between biologics and small molecules, targeted therapy approvals are coming more frequently, and pharmaceutical innovation remains relentless. 

Based on the Route of Administration, the Ankylosing Spondylitis Market can be divided into an oral route, an injectable route, and other formulations. Injectable formulations have the largest market share since biological products such as TNF inhibitors and IL-17 inhibitors are administered through injections to maximize effectiveness and quick impact.

Currently oral administration is less but, on the rise, due to patient-centred lesser invasive methods and the inclusion of oral drugs such as; Janus kinase (JAK) inhibitors. Subsequently, the higher usage of home healthcare solutions and self-administration kits has also added to the growth of the injectable segment. This classification is driven by advancements in technologies in drug delivery and the need to come up with differential methods of treatment to enhance patient compliance and performance. 

Regional Analysis

North America region is the largest region in the Ankylosing Spondylitis Market due to factors such as disease incidence, availability of a relatively sophisticated healthcare system, and the increasing use of biologic agents including TNF inhibitors and IL-17 blockers. This region has top pharma markets such as AbbVie, Amgen, and Pfizer, which proactively introduce new therapies and invest in plenty of clinical research. The last couple of years have brought to light new products including Cosentyx, and Taltz in North America reflecting a high-end treatment portfolio. Besides, increased childbirth rates, early diagnosis, and reimbursement policies that are more favorable in this region help to enhance the market growth in this region thereby maintaining its dominance. 

The Asia-Pacific region is the fastest-growing region in the Ankylosing Spondylitis Market because of an increase in disease awareness, better healthcare infrastructure, and an increased in-patient pool. Some aspects such as the cost of biosimilars and government policies promoting generic products have seen Countries like China and India opt for biosimilars. New strategies adopted in the current years involve the introduction of locally produced biosimilars like Adalimumab biosimilars and partnerships with research firms of multinational pharmaceutical companies. Customer awareness of healthcare and government initiatives on chronic diseases are driving the growth of this market and therefore Asia-Pacific continent is the future. 

Competitive Landscape

The Ankylosing Spondylitis Market has a highly competitive rivalry among main players in the market, such as AbbVie Inc., Amgen Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, UCB S.A. and Johnson & Johnson (Janssen Biotech, Inc.). These companies concentrate on the creation of biologics and biosimilars, which are more notable for anticipating illness and managing its advancement. For example, it can be stipulated that the market growth was preceded by AbbVie’s Humira and Amgen Company’s Enbrel. 

To maintain competitiveness in the market, players have begun adopting strategies such as acquisitions and mergers, joint ventures, and investments in research and development. For example, Novartis utilizes Cosentyx, an IL-17 inhibitor, and relies on clinical trial results to demonstrate the medication's efficacy. UCB S.A. has put much effort into developing new goods and services for the following Cimzia, especially considering the unmet demand among patients. Another important focus is biosimilars –affordable bioequivalent of biologics – for instance, the activities of Pfizer.

Ankylosing Spondylitis Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In September 2024, UCB, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and adults with active Ankylosing Spondylitis (AS).BIMZELX is the first approved treatment for these three indications that is designed to selectively inhibit two key cytokines driving inflammatory processes – interleukin 17A (IL-17A) and interleukin 17F (IL-17F).

Report Coverage:

By Drug Class

• Non-Steroidal Anti-Inflammatory Drugs
  • Ibuprofen
  • Naproxen
  • Others
• Tumor Necrosis Factor (TNF) Inhibitors
  • Etanercept
  • Infliximab
  • Adalimumab
  • Golimumab
• Interleukin-17 (IL-17) Inhibitors
  • Secukinumab
  • Ixekizumab
• Disease-modifying antirheumatic Drugs
  • Methotrexate
  • Sulfasalazine
• Corticosteroids
• Others

 By Route of Administration

• Oral
• Injectable
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

 By End-User

• Hospitals
• Specialty Clinics
• Homecare

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• AbbVie Inc.
• Amgen Inc.
• Pfizer Inc.
• Novartis AG
• Eli Lilly and Company
• UCB S.A.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Boehringer Ingelheim
• Janssen Biotech, Inc.
• Gilead Sciences
• Zydus Cadila
• Hetero
• Izana Bioscience
• Reliance Life Sciences Pvt. Ltd.
• Celltrion Healthcare
• Pozen
• Iroko Pharmaceuticals

Frequently Asked Questions (FAQs)